粪便
生物
大肠噬菌体
腹泻
安慰剂
噬菌体
肠道菌群
诺如病毒
微生物学
腹泻病
免疫学
胃肠病学
病毒
医学
大肠杆菌
遗传学
基因
替代医学
病理
作者
Shafiqul Alam Sarker,Bernard Berger,Deng Ying,Silas Kieser,Francis Foata,D Moine,Patrick Descombes,Shamima Sultana,Sayeeda Huq,Pradip Kumar Bardhan,Valérie Vuillet,Fabienne Praplan,Harald Brüssow
标识
DOI:10.1111/1462-2920.13574
摘要
A T4-like coliphage cocktail was given with different oral doses to healthy Bangladeshi children in a placebo-controlled randomized phase I safety trial. Fecal phage detection was oral dose dependent suggesting passive gut transit of coliphages through the gut. No adverse effects of phage application were seen clinically and by clinical chemistry. Similar results were obtained for a commercial phage preparation (Coliproteus from Microgen/Russia). By 16S rRNA gene sequencing, only a low degree of fecal microbiota conservation was seen in healthy children from Bangladesh who were sampled over a time interval of 7 days suggesting a substantial temporal fluctuation of the fecal microbiota composition. Microbiota variability was not associated with the age of the children or the presence of phage in the stool. Stool microbiota composition of Bangladeshi children resembled that found in children of other regions of the world. Marked variability in fecal microbiota composition was also seen in 71 pediatric diarrhea patients receiving only oral rehydration therapy and in 38 patients receiving coliphage preparations or placebo when sampled 1.2 or 4 days apart respectively. Temporal stability of the gut microbiota should be assessed in case-control studies involving children before associating fecal microbiota composition with health or disease phenotypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI